News

Monitoring CAVI May Improve COPD Management And Help Evaluate Disease Progression: Study
A new study highlights the Cardio-Ankle Vascular Index (CAVI) as a powerful tool for predicting COPD progression and outcomes ...
Pharmabiz9h
GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease
GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...
Health and Me on MSN12h
FDA Greenlights Nucala as New Treatment for COPD
FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...
FDA Approves Nucala for Chronic Obstructive Pulmonary Disease
By Stephanie Brown HealthDay ReporterFRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
GSK (LSE:GSK) Secures FDA Approval For COPD Treatment, Eyes European Nod For Blenrep
GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.
MedPage Today21h
FDA Approves Mepolizumab for COPD
Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...
PharmExec23h
FDA Approves GSK’s Nucala for Chronic Obstructive Pulmonary Disease
Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil counts as low as ≥150 cells/μL.
European Medical Journal23h
Breaking the silence: the patient-doctor perspective on new understanding and communication in COPD management
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to ...